Skip to Content

Jornay PM (methylphenidate) Disease Interactions

There are 16 disease interactions with Jornay PM (methylphenidate):

Major

CNS stimulants (Includes Jornay PM) ↔ agitation

Major Potential Hazard, High plausibility. Applies to: Anxiety/Stress, Neurosis, Psychosis

The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.

References

  1. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  2. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  3. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  4. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  5. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  6. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  7. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  8. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  9. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  10. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
View all 11 references
Major

CNS stimulants (Includes Jornay PM) ↔ cardiac disease

Major Potential Hazard, Moderate plausibility. Applies to: Heart Disease, Hypertension, Pheochromocytoma, Hyperthyroidism, Peripheral Arterial Disease

The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in adults and children taking CNS stimulant treatment. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.

References

  1. "Product Information. Dopram (doxapram)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
Major

CNS stimulants (Includes Jornay PM) ↔ glaucoma

Major Potential Hazard, Moderate plausibility. Applies to: Glaucoma/Intraocular Hypertension

The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.

References

  1. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  2. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
Major

CNS stimulants (Includes Jornay PM) ↔ hypertension

Major Potential Hazard, Moderate plausibility. Applies to: Hypertension

CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension. Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions. All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.

References

  1. "Product Information. Dopram (doxapram)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
Major

CNS stimulants (Includes Jornay PM) ↔ liver disease

Major Potential Hazard, Moderate plausibility. Applies to: Liver Disease

In general, CNS stimulants are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly. Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury. Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Major

CNS stimulants (Includes Jornay PM) ↔ substance abuse

Major Potential Hazard, High plausibility. Applies to: Alcoholism, Drug Abuse/Dependence

Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse. Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use. Frank psychotic episodes may also occur in association with chronic intoxication. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of amphetamines is considered by manufacturers to be contraindicated in such patients.

References

  1. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  3. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  4. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  5. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  6. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  7. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  8. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  9. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  10. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  11. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
View all 11 references
Major

CNS stimulants (Includes Jornay PM) ↔ tics

Major Potential Hazard, High plausibility. Applies to: Tic Disorder

Central nervous system (CNS) stimulants have been reported to exacerbate Tourette's syndrome and other motor and phonic tics. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  4. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  5. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  6. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  7. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  8. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  9. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  10. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  11. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
View all 11 references
Major

Methylphenidate (Includes Jornay PM) ↔ hypertension

Major Potential Hazard, High plausibility. Applies to: Hypertension

Methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer) exhibit sympathomimetic activity and may elevate blood pressure and pulse rate. Therapy with these agents should be administered cautiously in patients with hypertension. Blood pressure should be monitored periodically during therapy.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
Major

Methylphenidate (Includes Jornay PM) ↔ seizures disorders

Major Potential Hazard, High plausibility. Applies to: Seizures

There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities. Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures. The medication should be discontinued if seizures occur during its use.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
Moderate

CNS stimulants (Includes Jornay PM) ↔ bipolar disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Bipolar Disorder

Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.

Moderate

CNS stimulants (Includes Jornay PM) ↔ psychiatric disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Psychosis, Depression

The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. All patients receiving treatment should be screened for bipolar disease prior to initiation. If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. CNS stimulants are contraindicated in patients with marked agitation or anxiety.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Moderate

CNS stimulants (Includes Jornay PM) ↔ psychotic disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Psychosis

Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.

Moderate

CNS stimulants (Includes Jornay PM) ↔ renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response. The dosage should be adjusted accordingly.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Moderate

CNS stimulants (Includes Jornay PM) ↔ seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Seizures

Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures. These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures. Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures. If seizures appear, therapy should be discontinued.

References

  1. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Moderate

Methylphenidate (Includes Jornay PM) ↔ hematologic toxicity

Moderate Potential Hazard, Low plausibility. Applies to: Bone Marrow Depression/Low Blood Counts

Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate. However, a causal relationship has not been established. Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.

References

  1. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  2. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
Moderate

Methylphenidate ER (Includes Jornay PM) ↔ GI narrowing

Moderate Potential Hazard, High plausibility. Applies to: Gastrointestinal Obstruction

The extended-release formulation of methylphenidate (Concerta) contains a non-deformable material. There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products. The extended-release formulation of methylphenidate should ordinarily not be administered in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic (e.g., small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel's diverticulum). The medication should only be used in patients who are able to swallow the tablet whole.

References

  1. "Product Information. Concerta (methylphenidate)." Alza, Palo Alto, CA.

Jornay PM (methylphenidate) drug interactions

There are 114 drug interactions with Jornay PM (methylphenidate)

Jornay PM (methylphenidate) alcohol/food interactions

There are 4 alcohol/food interactions with Jornay PM (methylphenidate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.